Freezing breast tumors: a new hope for metastatic cancer control?

NCT ID NCT07676344

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study investigates cryoablation, a procedure that freezes and destroys tumor tissue, for treating the primary breast tumor in women with metastatic breast cancer. The goal is to see if this minimally invasive approach can control the local tumor for 12 months while patients continue their standard systemic therapy. The trial will also assess pain, quality of life, and safety. It includes 42 women whose metastatic disease is stable or responding to treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

cryoablation (freezing procedure)

What this could lead to

If successful, cryoablation could offer a minimally invasive option to control the primary breast tumor in metastatic breast cancer, potentially improving local symptoms and quality of life without interrupting systemic treatments.

What could go wrong

This is a small, early-phase study with only 42 participants, so results may not apply broadly. Cryoablation may not prevent tumor regrowth, and risks include infection, pain, or damage to nearby tissue.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Centre Hospitalier Lyon-Sud

    Lyon, 69 495, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••